0.55
+0.024(+4.60%)
Currency In USD
| Previous Close | 0.52 |
| Open | 0.54 |
| Day High | 0.56 |
| Day Low | 0.52 |
| 52-Week High | 3.39 |
| 52-Week Low | 0.5 |
| Volume | 2.01M |
| Average Volume | 6.63M |
| Market Cap | 24.26M |
| PE | -0.31 |
| EPS | -1.79 |
| Moving Average 50 Days | 1.53 |
| Moving Average 200 Days | 1.58 |
| Change | 0.02 |
If you invested $1000 in Outlook Therapeutics, Inc. (OTLK) since IPO date, it would be worth $0.8 as of January 18, 2026 at a share price of $0.546. Whereas If you bought $1000 worth of Outlook Therapeutics, Inc. (OTLK) shares 5 years ago, it would be worth $21.67 as of January 18, 2026 at a share price of $0.546.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Outlook Therapeutics Appoints Laura Cantrell as Vice President of Corporate Strategy and Business Development
GlobeNewswire Inc.
Jan 06, 2026 1:35 PM GMT
ISELIN, N.J., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced it has appointed
Outlook Therapeutics Announces New Employment Inducement Grants
GlobeNewswire Inc.
Dec 26, 2025 10:00 PM GMT
ISELIN, N.J., Dec. 26, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that effective De
Outlook Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference
GlobeNewswire Inc.
Nov 24, 2025 2:05 PM GMT
Live webcast fireside chat on Tuesday, December 2nd at 10:00 AM ETISELIN, N.J., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for t